Arcutis Biotherapeutics, Inc. (ARQT) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Mizuho Reiterates Outperform Rating on Arcutis Biotherapeutics Inc. (ARQT)
August 16, 2024 2:59 PM EDTMizuho analyst Uy Ear reiterated an Outperform rating and $19.00 price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT)
The analyst comments "For the week ending 08/09/2024, the Zoryve franchise grew 10.5% (vs +4.2% in the prior week) for TRxs and 6.3% (vs +12.4% in the prior week) for... More
